Shares of Reata Pharmaceuticals Inc. (RETA) rose 8% to $82.35 after the company said it re-acquired development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie Inc. (ABBV) for territories outside of the U.S. with respect to bardoxolone methyl and world-wide with respect to omaveloxolone and other next-generation Nrf2 activators.
Shares of Reata closed down 5% Wednesday.
The Texas-based biopharmaceutical company said it now possesses exclusive, world-wide rights to develop, manufacture and commercialize bardoxolone methyl, omaveloxolone, and all other next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone, which are licensed to Kyowa Kirin Co. Ltd.
Reata said AbbVie will receive $330 million in cash, primarily for rights to bardoxolone. Reata will make an upfront payment of $75 million in 2019, with the remainder payable in installments in the second quarter of 2020 and in the fourth quarter of 2021. In addition, AbbVie will receive low-single-digit, tiered royalties from world-wide sales of omaveloxolone and certain next-generation Nrf2 activators, and no royalties on bardoxolone.
Reata also said it has entered into an amendment to its loan and security agreement with Oxford Finance LLC and Silicon Valley Bank. The amended agreement makes $75 million available to Reata upon positive, topline, registrational data from either the Cardinal study of bardoxolone methyl in patients with Alport syndrome or the MOXIe study of omaveloxolone in patients with Friedreich's ataxia. The term loan facility increased by $30 million to $155 million.